{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:43:59Z","timestamp":1793054639913,"version":"4.5.0"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T00:00:00Z","timestamp":1643932800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Previous treatment for macrophage activation syndrome (MAS) includes high-dose intravenous methylprednisolone along with intravenous immunoglobulin G. If MAS worsened, second-line therapy consisted of anakinra; if the disease remained refractory, third-line therapy with etoposide was considered. In addition, cyclosporine A plays a role in early MAS and in preventing recurrence. Some studies have reported the use of cytokine-targeting agents other than anakinra, such as canakinumab, tocilizumab, abatacept, and tofacitinib.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>The patient with systemic lupus erythematosus (SLE) had an uncommon combination of intermittent fever, hyperferritinemia, hypertriglyceridemia, jaundice, and significantly abnormal liver function test results. The patient reported a history of daily fever of 38 to 39\u00b0C, painful oral ulcer, anorexia, abdominal bloating, diarrhea, and malar rash progression for 2\u200aweeks, and jaundice, tea-colored urine, and clay-colored stool for 1 week preceding hospital admission.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>SLE flareups in the patient were initially suspected. However, the final diagnosis was acute respiratory distress syndrome (ARDS) associated with MAS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The treatment included disease-modifying antirheumatic drugs (DMARDs), such as azathioprine, and titrated steroid doses of methylprednisolone (40\u200amg q8\u200ah) and dexamethasone (15\u200amg q8\u200ah), after the patient had ARDS and was intubated.<\/jats:p>\n            <jats:p>Dose-adjusted monotherapy with dexamethasone was found to be effective; this may be attributed to some DMARDs being unsuitable for cytokine storms, that is, some DMARDs may cause complications in cytokine storms.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>After dexamethasone 15\u200amg q8\u200ah treatment, the patient's fever subsided within 2\u200adays, and liver function became normal within 3\u200aweeks. The patient regularly attended scheduled outpatient follow-up visits after discharge. After 2\u200ayears, the patient reported no symptoms or signs of SLE with 2\u200amg\/d oral dexamethasone.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Early diagnosis of MAS and dexamethasone treatment for MAS with ARDS appear to be crucial for these patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000028612","type":"journal-article","created":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T13:01:08Z","timestamp":1643979668000},"page":"e28612","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Acute respiratory distress syndrome associated with macrophage activation syndrome in systemic lupus erythematosus"],"prefix":"10.1097","volume":"101","author":[{"given":"En-Shuo","family":"Chang","sequence":"first","affiliation":[{"name":"Division of Nephrology, China Medical University Hsinchu Hospital, Hsinchu, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Hua","family":"Yu","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Linkou branch, Taoyuan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiao-En","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou branch, Taiwan"},{"name":"Chang Gung University College of Medicine, Taoyuan, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0753-4529","authenticated-orcid":false,"given":"Tien-Ming","family":"Chan","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Linkou branch, Taoyuan, Taiwan"},{"name":"Chang Gung University College of Medicine, Taoyuan, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,2,4]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(13)61048-X","article-title":"Adult haemophagocytic syndrome","volume":"383","author":"Ramos-Casals","year":"2014","journal-title":"Lancet"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"05","DOI":"10.1093\/rheumatology\/key006","article-title":"Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment","volume":"58","author":"Carter","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1177\/0961203314529467","article-title":"Clinical features of macrophage activation syndrome in the adult northern Chinese population","volume":"23","author":"Li","year":"2014","journal-title":"Lupus"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/art.38690","article-title":"Development and validation of the Hscore, a score for the diagnosis of reactive hemophagocytic syndrome","volume":"66","author":"Fardet","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"2324709618812196","DOI":"10.1177\/2324709618812196","article-title":"A rare case of macrophage activation syndrome presenting as the first manifestation of systemic lupus erythematosus","volume":"6","author":"Poudel","year":"2018","journal-title":"J Investig Med High Impact Case Rep"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3389\/fimmu.2019.00119","article-title":"The immunology of macrophage activation syndrome","volume":"10","author":"Crayne","year":"2019","journal-title":"Front Immunol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1177\/0961203309354906","article-title":"Hemophagocytic syndrome as one of the main primary manifestations in acute systemic lupus erythematosus \u2013 case report and literature review","volume":"19","author":"Carvalheiras","year":"2010","journal-title":"Lupus"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"962","DOI":"10.3109\/14397595.2013.844402","article-title":"Successful treatment of macrophage activation syndrome in a patient with dermatomyositis by combination with immunosuppressive therapy and plasmapheresis","volume":"25","author":"Kaieda","year":"2015","journal-title":"Mod Rheumatol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3109\/14397595.2014.906053","article-title":"Successful therapy of macrophage activation syndrome with dexamethasone palmitate","volume":"26","author":"Nakagishi","year":"2016","journal-title":"Mod Rheumatol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028612","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:07:07Z","timestamp":1746331627000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028612"}},"subtitle":["A case report and literature review"],"short-title":[],"issued":{"date-parts":[[2022,2,4]]},"references-count":10,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000028612","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,4]]},"assertion":[{"value":"2021-12-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}